Correction of chromosomal point mutations in human cells with bifunctional oligonucleotides

Nature Biotechnology

Volumn 17, Issue 10, 1999, Pages 989-993

  Culver, Kenneth W ^a,b   Hsieh, Wang Ting ^a   Huyen, Yentram ^a   Chen, Vivian ^a   Liu, Jilan ^a   Khripine, Yuri ^a,c   Khorlin, Alexander ^a,d  

^a Division of Medicinal Chemistry   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Intergen Discovery Products   (United States)

^d Genelabs Incorporated   (United States)

Author keywords

Adenosine deaminase; Gene repair; Gene therapy; Triplexing oligonucleotides

Indexed keywords

ADENOSINE DEAMINASE; OLIGODEOXYNUCLEOTIDE; OLIGONUCLEOTIDE; PROTEIN P53;

APOPTOSIS; ARTICLE; BINDING SITE; CHROMOSOME MUTATION; CONTROLLED STUDY; GENE TARGETING; GENE THERAPY; GLIOBLASTOMA; HUMAN; HUMAN CELL; LYMPHOCYTE; POINT MUTATION; PRIORITY JOURNAL;

EID: 0032874955     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/13684     Document Type: Article

References (40)

1. Kunzelmann, K. et al. Gene targeting of CFTR DNA in CF epithelial cells. Gene Ther. 10, 859-867 (1996).
2. Cole-Strauss, A. et al. Correction of the mutation responsible for sickle cell anemia by an RNA-DNA oligonucleotide. Science 273, 1386-1389 (1996).
3. Russell D.W. & Hirata, R.K. Human gene targeting by viral vectors. Nat. Genet. 18, 325-330 (1998).
4. Chan, P.P. & Glazer, P.M. Triplex DNA: fundamentals, advances, and potential applications for gene therapy. J. Mol. Med. 75, 267-282 (1997).
5. Hanvey, J.C., Williams, E.M. & Besterman J.M. DNA triple-helix formation at physiological pH and temperature. Antisense Res. Dev. 1, 307-317 (1991).
6. Hsieh, P., Camerini-Otero, C.S. & Camerini-Otero, R.D. The synapsis event in the homologous pairing of DNAs: RecA recognizes and pairs less than one helical repeat of DNA. Proc. Natl Acad. Sci. USA 89, 6492-6496 (1992).
7. Rao, B.J. & Radding, C.M. Formation of base triplets by non-Watson-Crick bonds mediates homologous recognition in RecA recombination filaments. Proc. Natl Acad. Sci. USA 91, 6161-6165 (1994).
8. Yanez, R.J. & Porter, A.C. Therapeutic gens targeting. Gene Ther. 5, 149-159 (1998).
9. Griffin, L.C. & Dervan, P.B. Recognition of thymine-adenine base pairs by guanine in a pyrimidine triple helix motif. Science 245, 967-971 (1989).
10. Fossella, J.A., Kim, Y.J., Shih, H., Richards, E.G. & Fresco, J.R. Relative specificities in binding of Watson-Crick base pairs by third strand residues in a DNA pyrimidine triplex motif. Nucleic Acids Res. 21, 4511-4515 (1993).
11. Vlieghe, D. et al. Parallel and antiparallel (G·GC)2 triple helix fragments in a crystal structure. Science 273, 1702-1706 (1996).
12. Majumdar, A. et al. Targeted gene knockout mediated by triple helix forming oligonucleotides. Nat. Genet. 20, 2112-2214 (1998).
13. Svinarchuk, F. et al. Recruitment of transcription factors to the target site by triplex-forming oligonucleotides. Nucleic Acids Res. 25, 3459-3464 (1997).
14. 125I labeled oligonucleotides. Nucleic Acids Res. 22, 4979-4982 (1994).
15. Grigonev, M. et al. A triple helix-forming oligonucleotide-intercalator conjugate acts as a transcriptional repressor via inhibition of NF kappa B binding to interleukin-2 receptor alpha-regulatory sequence. J. Biol. Chem. 267, 3389-3395 (1992).
16. Escude, C. et al. Rational design of a triple helix-specific intercalating ligand. Proc. Natl Acad. Sci. USA 95, 3591-3596 (1998).
17. Wang, G., Levy, D.D., Seidman, M.M. & Glazer, P.M. Targeted mutagenesis in mammalian cells mediated by intracellular triple helix formation. Mol. Cell. Biol. 15, 1759-1768 (1995).
18. Volkmann, S., Jendis, J., Frauendorf, A. & Moelling, K. Inhibition of HIV-1 reverse transcription by triple-helix forming oligonucleotides with viral RNA. Nucleic Acids Res. 23, 1204-1212 (1995).
19. Sun, J.S., Garestier, T. & Helene, C. Oligonucleotide directed triple helix formation. Curr. Opin. Struct. Biol. 8, 327-333 (1996).
20. Gamper, Jr. H.B., Hou, Y.-M., Stamm, M.R., Podyminogin, M.A. & Meyer, R.B. Strand invasion of supercoiled DNA by oligonucleotides with a triplex guide sequence. J. Am. Chem. Soc. 120, 2182-2183 (1998).
21. Chan et al. Targeted correction of an episomal gene in mammalian cells by a short DNA fragment tethered to a triplex-forming oligonucleotide. J. Biol. Chem. 274, 11541-11546 (1999).
22. Hirschhorn, R. Adenosine deaminase deficiency: molecular basis and recent developments. Clin. Immunol. Pathol. 76, 219-227 (1995).
23. Blaese, R.M., Culver, K.W. & Anderson, W.F. The ADA human gene therapy clinical protocol. Hum. Gene Ther. 1, 331-362 (1990).
24. Markert, M.L., Norby-Slycord, C. & Ward, F.E. A high proportion of ADA point mutations associated with a specific alanine-to-valine substitution. Am. J. Hum. Genet. 45, 354-361 (1989).
25. Hirschhorn, R., Martiniuk, F. & Rosen, F.S. Adenosine deaminase activity in normal tissues and tissues from a child with severe combined immunodeficiency and adenosine deaminase deficiency. Clin. Immunol. Immunopathol. 9, 287-292 (1978).
26. Hussain, S.P. & Harris, C.C. Molecular epidemiology of human cancer: Contribution of mutation spectra studies of tumor suppressor genes. Cancer Res. 58, 4023-4037 (1998).
27. Fujiwara, T. et al. Retroviral-mediated transduction of p53 gene increases TGF-beta expression in a human glioblastoma cell line. Int. J. Cancer 56, 834-839 (1994).
28. Wang, G., Seidman, M.M. & Glazer, P.M. Mutagenesis in mammalian cells induced by triple helix formation and transcription-coupled repair. Science 27, 802-805 (1996).
29. Sturzbecher, H.W., Donzelmann, B., Henning, W., Knippschild, U. & Buchhop, S. p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction. EMBO J. 15, 1992-2002 (1996).
30. Seto, S., Carrera, C.J., Wasson, D.B. & Carson, D.A. Inhibition of DNA repair by deoxyadenosine in resting human lymphocytes. J. Immunol. 136, 2839-2843 (1986).
31. Goncz, K.K., Kunzelmann, K., Xu, Z., & Gruenert, D.C. Targeted replacement of normal and mutant CFTR sequences in human airway epithelial cells using DNA fragments. Hum. Mol. Genet. 7, 1913-1919 (1998).
32. Cole-Strauss, A. et al. Correction of the mutation responsible for sickle cell anemia by an RNA-DNA oligonucleotide. Science 273, 1386-1389 (1996).
33. Kren, B.T., Cole-Strauss, A., Kmiec, E.B. & Steer, C.J. Targeted nucleotide exchange in the alkaline phosphatase gene of HuH-7 cells mediated by a chimeric RNA/DNA oligonucleotide. Hepatology 25, 1462-1468 (1997).
34. Strauss, M. The site-specific correction of genetic defects. Nat. Med. 4, 274-275 (1998).
35. Blaese, R. M. et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 270, 475-480 (1995).
36. Maher, L.J., Dervan, P.B & Wold, B. Kinetic analysis of oligodeoxyribonucleotide-directed triple-helix formation on DNA. J. Biochem. 29, 8820-8826 (1990).
37. Agrawal, S. et al. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. Proc. Natl. Acad. Sci USA 94, 2620-2625 (1997).
38. Tang, M.X., Redemann, C.T. & Szoka, Jr., F.C. In vitro gene delivery by degraded polyamidoamine dendrimers. Bioconjugate Chem. 7, 703-714 (1996).
39. Culver, K.W. et al. Lymphocytes as cellular vehicles for gene therapy in mouse and man. Proc. Natl Acad. Sci. USA 88, 3155-3159 (1991).
40. Li, X. et al. Application of biotin, digoxigenin or fluorescein conjugated deoxynucleotides to label DNA strand breaks for analysis of cell proliferation and apoptosis using flow cytometry. Biotech. Histochem. 70, 234-242 (1995).